News >

Immunotherapy Advances to Frontline in NSCLC, But More Work Remains

Brittany Cote
Published: Thursday, Feb 20, 2020

Ronald Natale, MD, medical director, Clinical Lung Cancer Program, assistant clinical professor, Cedars-Sinai

Ronald Natale, MD

While there has been an explosion of immune checkpoint inhibitors in the lung cancer treatment paradigm, greater research efforts are still needed to determine optimal biomarkers for immunotherapy response, explained Ronald Natale, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication